About PathologyWatch
PathologyWatch is a company based in Salt Lake City (United States) founded in 2018 by Dan Lambert, Michael Torno, and Gregory Osmond was acquired by Sonic Healthcare in November 2023. PathologyWatch has raised $34.34 million across 4 funding rounds from investors including Sonic Healthcare, Ceros Capital Markets and Rock Creek Capital. PathologyWatch offers products and services including Digital Slides Access and EMR Integration. PathologyWatch operates in a competitive market with competitors including Skin Analytics, Haut, 3Derm, Nia Health and Love My Delta, among others.
- Headquarter Salt Lake City, United States
- Founders Dan Lambert, Michael Torno, Gregory Osmond
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$34.34 M (USD)
in 4 rounds
-
Latest Funding Round
$25 M (USD), Series B
Nov 16, 2021
-
Investors
Sonic Healthcare
& 13 more
-
Employee Count
Not available
-
Acquired by
Sonic Healthcare
(Nov 16, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of PathologyWatch
PathologyWatch offers a comprehensive portfolio of products and services, including Digital Slides Access and EMR Integration.
Provides 24/7 access to digital pathology slides for review
Automates report integration into electronic medical records for efficiency
People of PathologyWatch
Unlock access to complete
Unlock access to complete
Funding Insights of PathologyWatch
PathologyWatch has successfully raised a total of $34.34M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $25 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in PathologyWatch
PathologyWatch has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Sonic Healthcare, Ceros Capital Markets and Rock Creek Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are focused on tech startups.
|
Locked | Locked | Locked | |
|
Private equity and venture investments are provided to build businesses.
|
Locked | Locked | Locked | |
|
Early-stage tech startups are invested in by Spark Growth Ventures.
|
Locked | Locked | Locked |
Investor details for PathologyWatch
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PathologyWatch
Investment portfolio details for PathologyWatch
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PathologyWatch
Detailed financials for PathologyWatch
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pathologywatch Comparisons
Peer comparison for PathologyWatch
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PathologyWatch
PathologyWatch operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Skin Analytics, Haut, 3Derm, Nia Health and Love My Delta, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of smartphone based skin cancer detection
|
|
| Locked | Locked | Locked |
SaaS solutions using AI for skincare businesses are provided.
|
|
| Locked | Locked | Locked |
Skin images are analyzed digitally for disease detection by dermatologists.
|
|
| Locked | Locked | Locked |
Digital therapeutics are provided for personalized dermatology and allergology support.
|
|
| Locked | Locked | Locked |
AI-based skin analysis tool for wellness, beauty, and aesthetic medicine
|
Detailed competitors of PathologyWatch
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pathologywatch
Complete news archive for PathologyWatch
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PathologyWatch
PathologyWatch was founded in 2018 and raised its 1st funding round 1 year after it was founded.
PathologyWatch is headquartered in Salt Lake City, United States. It is registered at Salt Lake City, Utah, United States.
Dan Lambert is the current CEO of PathologyWatch. They have also founded this company.
PathologyWatch is a funded company, having raised a total of $34.34M across 4 funding rounds to date.
PathologyWatch offers clinical workflow management and decision-making software and services for professionals. The software platform enables the pathologist to upload a digital sample of slides in the cloud and automate the result to their EHR system for hospital operations. The company provides services for digital pathology, dermatopathology where samples can be sent to the company for biopsy and interpretation. Products like PathologyWatch, ValueWatch, and Business watch assist with the laboratory functions and operations like remote image viewing, Electronic Medical Records integration, and more.
PathologyWatch's top competitors include Skin Analytics, 3Derm and Haut.
PathologyWatch offers Digital Slides Access and EMR Integration.
PathologyWatch has 14 investors. Key investors include Sonic Healthcare, Ceros Capital Markets, Rock Creek Capital, Spark Growth Ventures, and Blueprint Health.